Vadadustat 900mg + Vadadustat 1200mg + Placebo
Phase 2/3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonintubated Acute Respiratory Distress Syndrome (ARDS)
Conditions
Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury
Trial Timeline
Oct 23, 2025 → Jul 1, 2026
NCT ID
NCT07086755About Vadadustat 900mg + Vadadustat 1200mg + Placebo
Vadadustat 900mg + Vadadustat 1200mg + Placebo is a phase 2/3 stage product being developed by Akebia Therapeutics for Nonintubated Acute Respiratory Distress Syndrome (ARDS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07086755. Target conditions include Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury.
Hype Score Breakdown
Clinical
15
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07086755 | Phase 2/3 | Recruiting |